Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen

Purpose The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening. We conducted this review to estimate the associations between BMI and (1) prostate...

Full description

Bibliographic Details
Main Authors:	Harrison, S, Tilling, K, Turner, EL, Martin, RM, Lennon, R, Lane, JA, Donovan, JL, Hamdy, FC, Neal, DE, Bosch, JLHR, Jones, HE
Format:	Journal article
Language:	English
Published:	Springer 2020

Similar Items

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
by: Harrison, S, et al.
Published: (2016)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
by: Brindle, L, et al.
Published: (2006)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
by: Macefield, R, et al.
Published: (2009)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
by: Young, GJ, et al.
Published: (2017)

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
by: Moore, A, et al.
Published: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
by: Avery, K, et al.
Published: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
by: Avery, K, et al.
Published: (2012)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
by: Turner, E, et al.
Published: (2011)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
by: Hamdy, F, et al.
Published: (2006)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

Screening for prostate cancer. The case against.
by: Donovan, J, et al.
Published: (2005)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
by: Tilling, K, et al.
Published: (2010)

Radiotherapy for prostate cancer: is it 'what you do' or 'the way that you do it'? A UK perspective on technique and quality assurance.
by: Mason, MD, et al.
Published: (2016)

Metabolic imbalance and prostate cancer progression.
by: Burton, A, et al.
Published: (2010)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
by: Simpkin, A, et al.
Published: (2013)

10-year outcomes in localized prostate cancer.
by: Hamdy, F, et al.
Published: (2017)

Screening for prostate cancer remains controversial.
by: Neal, D, et al.
Published: (2009)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
by: Govinda Nanjaiah Laxmana Raju, et al.
Published: (2023-06-01)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
by: Lane, J, et al.
Published: (2009)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

10-year outcomes in localized prostate cancer: Authors' reply
by: Hamdy, F, et al.
Published: (2017)

Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer
by: Youngjun Boo, et al.
Published: (2023-07-01)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
by: Collin, S, et al.
Published: (2010)

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
by: Bai X, et al.
Published: (2020-08-01)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

First report of prostate-specific membrane antigen-targeted immunotherapy in prostate cancer: the future is bright
by: Lamb, A, et al.
Published: (2018)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
by: Avery, K, et al.
Published: (2008)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
by: Lane, J, et al.
Published: (2007)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

The Impact of prostate – Specific Antigen Density In Predicting Prostate Cancer
by: Abdul-Kareem Sh. Al-Khafaji, et al.
Published: (2019-11-01)